Open AccessDeveloping a Drug Screening Platform: MALDI-Mass Spectrometry Imaging of Paper-Based Cultures
Author(s) -
Fernando Tobias,
Julie C. McIntosh,
Gabriel J. LaBonia,
Matthew W. Boyce,
Matthew R. Lockett,
Amanda B. Hummon
Publication year - 2019
Publication title -
analytical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.117
H-Index - 332
eISSN - 1520-6882
pISSN - 0003-2700
DOI - 10.1021/acs.analchem.9b03536
Subject(s) - chemistry , matrigel , mass spectrometry , in vivo , 3d cell culture , drug discovery , drug , mass spectrometry imaging , in vitro , cell culture , chromatography , nanotechnology , pharmacology , biochemistry , microbiology and biotechnology , medicine , genetics , materials science , biology
Many potential chemotherapeutics fail to reach patients. One of the key reasons is that compounds are tested during the drug discovery stage in two-dimensional (2D) cell cultures, which are often unable to accurately model in vivo outcomes. Three-dimensional (3D) in vitro tumor models are more predictive of chemotherapeutic effectiveness than 2D cultures, and thus, their implementation during the drug screening stage has the potential to more accurately evaluate compounds earlier, saving both time and money. Paper-based cultures (PBCs) are an emerging 3D culture platform in which cells suspended in Matrigel are seeded into paper scaffolds and cultured to generate a tissue-like environment. In this study, we demonstrate the potential of matrix-assisted laser desorption/ionization-mass spectrometry imaging with PBCs (MALDI-MSI-PBC) as a drug screening platform. This method discriminated regions of the PBCs with and without cells and/or drugs, indicating that coupling PBCs with MALDI-MSI has the potential to develop rapid, large-scale, and parallel mass spectrometric drug screens.